Malignant pheochromocytoma and paraganglioma: Future considerations for therapy

R. Buzzoni, S. Pusceddu, A. Damato, E. Meroni, C. Aktolun, M. Milione, V. Mazzaferro, F. De Braud, C. Spreafico, M. Maccauro, N. Zaffaroni, M. R. Castellani

Research output: Contribution to journalArticlepeer-review


Pheochromocytoma and paraganglioma are rare neuroendocrine tumors. Knowledge about such neoplasms ameliorated in the last 10-15 years with the discovery of increasing number of germ line mutations even in apparently sporadic cases. Seemingly, genetic tests are going to be an integral part of diagnostic procedures. Standard therapies (advanced surgery, radiometabolic therapy, chemotherapy and radiotherapy) have revealed suboptimal results in tumor size reduction and survival. Currently, there is no standard therapeutic protocol and thus some patients end up with overtreatment while others are undertreated. An effective molecular target therapy aiming at permanent control of these highly complex neoplasms should be the aim of future efforts. In clinical setting investigatory trials with multiple drug therapies targeting a variety of different parallel pathways should be available. Successful management requires a multidisciplinary teamwork.

Original languageEnglish
Pages (from-to)153-160
Number of pages8
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Issue number2
Publication statusPublished - Jun 2013


  • Molecular targeted therapy
  • Neuroendocrine tumors
  • Paraganglioma
  • Pheochromocytoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Malignant pheochromocytoma and paraganglioma: Future considerations for therapy'. Together they form a unique fingerprint.

Cite this